ALG-LungCancerRegistry (SAFRO2202)

计划入组 3,750 人 · 首次发布于 2025 年 9 月 9 日

APG-115 in Salivary Gland Cancer Trial

计划入组 41 人 · 首次发布于 2018 年 12 月 20 日

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Renal Impairment and in Healthy Subjects With Normal Renal Function

计划入组 12 人 · 首次发布于 2024 年 11 月 21 日

ALG-009

ALG-125755

ALG-000184

Afferent Pharmaceuticals, Inc.

United States

FUKUOKA UNIVERSITY

Japan

Prescient Therapeutics Ltd.

Australia

Allogenetics Appoints Dr. Jeroen Rovers as Chief Medical Officer to Advance ALG-115 Toward Clinical Trials in Lung Transplantation

Allogenetics Raises €3.8M Pre-Series A to Advance Ex Vivo Gene Therapy for Rejection-Resistant Donor Lungs

Aligos Therapeutics' ALG-000184 Receives FDA IND Clearance for Hepatitis B